Cargando…
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
NAMI-A ((ImH)[trans-RuCl(4)(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl(4)(Ind)(2)], Ind = indazole; KP1339 = Na[trans-RuCl(4)(Ind)(2)]) are two structurally related ruthenium(III) coordination compounds that have attracted a lot of attention in the medicinal inorganic...
Autores principales: | Alessio, Enzo, Messori, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571951/ https://www.ncbi.nlm.nih.gov/pubmed/31137659 http://dx.doi.org/10.3390/molecules24101995 |
Ejemplares similares
-
DMSO reduces the cytotoxicity of anticancer ruthenium complex KP1019 in yeast
por: Davis, Jonathan, et al.
Publicado: (2021) -
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
por: Heffeter, Petra, et al.
Publicado: (2013) -
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion
por: Bergamo, A., et al.
Publicado: (2009) -
Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD‐100/KP1339 in the Endoplasmic Reticulum
por: Neuditschko, Benjamin, et al.
Publicado: (2021) -
A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)
por: Golla, Upendarrao, et al.
Publicado: (2017)